Status:
COMPLETED
Early PP With HFNC Versus HFNC in COVID-19 Induced Moderate to Severe ARDS
Lead Sponsor:
Rush University Medical Center
Conditions:
Prone Positioning
High Flow Nasal Cannula
Eligibility:
All Genders
18+ years
Phase:
NA
Brief Summary
Coronavirus disease 2019 (COVID-19) is an emerging infectious disease that was first reported in Wuhan, China, and had subsequently spread worldwide. Twenty-nine percent of COVID-19 patients may devel...
Eligibility Criteria
Inclusion
- COVID-19 induced adult ARDS patients admitted to the medical ICU
- PaO2/FiO2 is less than 200mmHg or FIO2 ≥ 0.4 is required to maintain SpO2 at 88-93% on HFNC treatment
Exclusion
- If the patients have a consistent SpO2\<80% when on evaluation with a FiO2 of 0.6, or signs of respiratory fatigue (RR \> 40/min, PaCO2\> 50mmHg / pH\<7.30, and obvious accessory respiratory muscle use);
- Immediate need for intubation (PaO2/FiO2\< 50mmHg or SpO2/FiO2 \<90, unable to protect airway or mental status change);
- unstable hemodynamic status(SBP\<90mmHg, MBP below 65 mmHg or requirement for vasopressor);
- unable to collaborate with HFNC/PP with agitation or refuse HFNC/PP.
- chest trauma or any contraindication for PP
- pneumothorax
- age \< 18 years
Key Trial Info
Start Date :
April 2 2020
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 21 2021
Estimated Enrollment :
224 Patients enrolled
Trial Details
Trial ID
NCT04325906
Start Date
April 2 2020
End Date
February 21 2021
Last Update
March 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Rush University Medical Center
Chicago, Illinois, United States, 60612